Pimecrolimus 1% cream for the treatment of seborrheic dermatitis: a systematic review of randomized controlled trials.

Abstract

Seborrheic dermatitis is a common, chronic, relapsing inflammatory skin disorder that manifests as erythema, scaling and pruritus in sebum gland-rich areas of the skin. The objective of this article is to evaluate the clinical efficacy of pimecrolimus 1% cream in the treatment of seborrheic dermatitis compared with corticosteroids, antimycotics, placebo or no intervention. Pimecrolimus 1% cream appears to be a well-tolerated and effective treatment for seborrheic dermatitis. It has comparable efficacy, in terms of decreasing severity of erythema, scaling and pruritus, to the standard treatments: topical corticosteroids and antimycotics. However, future studies with more standardized measures of treatment outcome are recommended. More studies may also be conducted to further evaluate pimecrolimus 1% cream as a long-term maintenance therapy for seborrheic dermatitis.

• Authors: Charlene U Ang-Tiu, Chandra F Meghrajani, Clarita C Maano
• Journal: Expert review of clinical pharmacology (Expert Rev Clin Pharmacol) Vol. 5 Issue 1 Pg. 91-7 (Jan 2012) ISSN: 1751-2441 [Electronic] England
• PMID: 22142161 (Publication Type: Journal Article, Review, Systematic Review)

Chemical References

• Calcineurin Inhibitors
• Dermatologic Agents
• pimecrolimus
• Tacrolimus

Topics

• Administration, Cutaneous
• Animals
• Calcineurin Inhibitors
• Chemistry, Pharmaceutical
• Dermatitis, Seborrheic (drug therapy, pathology)
• Dermatologic Agents (administration & dosage, chemistry)
• Humans
• Randomized Controlled Trials as Topic (methods)
• Tacrolimus (administration & dosage, analogs & derivatives, chemistry)
• Treatment Outcome